| Jul 22 |
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
|
| Jul 11 |
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
|
| Jul 9 |
Zymeworks: A Somewhat Complicated Story
|
| Jun 17 |
Zymeworks ZW171 IND for mesothelin-expressing cancers cleared by FDA
|
| Jun 17 |
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
|
| Jun 15 |
Zymeworks (NASDAQ:ZYME) investors are sitting on a loss of 75% if they invested three years ago
|
| Jun 10 |
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
|
